696 related articles for article (PubMed ID: 27797957)
1. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.
Pommier Y; O'Connor MJ; de Bono J
Sci Transl Med; 2016 Oct; 8(362):362ps17. PubMed ID: 27797957
[TBL] [Abstract][Full Text] [Related]
2. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
3. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
Li N; Wang Y; Deng W; Lin SH
Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
5. [PARP inhibitors--theoretical basis and clinical application].
Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitors in the management of breast cancer: current data and future prospects.
Livraghi L; Garber JE
BMC Med; 2015 Aug; 13():188. PubMed ID: 26268938
[TBL] [Abstract][Full Text] [Related]
7. [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
Kluzek K; Białkowska A; Koczorowska A; Zdzienicka MZ
Postepy Hig Med Dosw (Online); 2012 Jun; 66():372-84. PubMed ID: 22706123
[TBL] [Abstract][Full Text] [Related]
8. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
9. Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells.
Trafalis DT; Polonifi A; Dalezis P; Nikoleousakos N; Katsamakas S; Sarli V
Chem Biol Drug Des; 2017 Nov; 90(5):854-866. PubMed ID: 28432813
[TBL] [Abstract][Full Text] [Related]
10. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
[TBL] [Abstract][Full Text] [Related]
11. PARP inhibitors and stratified treatment of prostate cancer.
Lavery A; Gilson C; Chowdhury S
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1213-1215. PubMed ID: 27686597
[No Abstract] [Full Text] [Related]
12. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?
Hottiger MO
Expert Opin Ther Targets; 2015; 19(9):1149-52. PubMed ID: 26212149
[TBL] [Abstract][Full Text] [Related]
14. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibitors: targeting the right patients.
Azvolinsky A
J Natl Cancer Inst; 2012 Dec; 104(24):1851-2. PubMed ID: 23231976
[No Abstract] [Full Text] [Related]
17. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
18. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
19. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Li Y; Liu CF; Rao GW
Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
[TBL] [Abstract][Full Text] [Related]
20. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
